Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Biogen on Tuesday agreed to pay $165 million ... The Stifel team spoke to physicians, who were clear that the efficacy bar zorevunersen needs to meet is “very high.” ...
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results